Lumida
/VRDN
⌘K
Viridian Therapeutics Inc

Viridian Therapeutics Inc

VRDN
$18.03USD+0.00%+0.00 today

MARKET CAP

2.0B

P/E (TTM)

FWD P/E

DAY RANGE

$18 – $18

52W RANGE

$13
$34

AI Summary

Stalk
StalkMedium

VRDN remains in a Stage 2 advancing regime within the broader uptrend, but near-term price is extended above rising EMAs with extreme overbought readings. Medium-term structure stays bullish with a clear HH/HL sequence intact, yet execution is deferred—awaiting a shallow pullback into the 9/21 EMA support zone for disciplined entry.

  • FDA approved Lumvoa for active & chronic TED in $4B+ market
  • VRDN001 delivered 75% proptosis response rate in pivotal trials
  • Persistent losses and weak profitability raise sustainability concerns
Full analysis →
Insider Trades11 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Mar 3, 2026SellVRDNJennifer TousignantChief Legal Officer1,724$29.32$2.0B-47.42%+36.80%$50.5K-1.05%Stalk
Mar 3, 2026SellVRDNJennifer TousignantChief Legal Officer1,675$30.19$2.0B-47.42%+36.80%$50.6K-32.40%Stalk
Mar 3, 2026SellVRDNSeth HarmonChief Financial Officer2,091$29.32$2.0B-47.42%+36.80%$61.3K-1.37%Stalk
Mar 3, 2026SellVRDNSeth HarmonChief Financial Officer2,031$30.19$2.0B-47.42%+36.80%$61.3K-20.55%Stalk
Mar 3, 2026SellVRDNThomas W. BeethamChief Operating Officer3,138$29.32$2.0B-47.42%+36.80%$92.0K-1.22%Stalk
Mar 3, 2026SellVRDNThomas W. BeethamChief Operating Officer3,048$30.19$2.0B-47.42%+36.80%$92.0K-18.58%Stalk
Mar 3, 2026SellVRDNStephen F. MahoneyPresident and CEO7,627$29.32$2.0B-47.42%+36.80%$223.6K-0.99%Stalk
Mar 3, 2026SellVRDNStephen F. MahoneyPresident and CEO7,408$30.19$2.0B-47.42%+36.80%$223.6K-18.18%Stalk
Dec 31, 2025SellVRDNJennifer TousignantChief Legal Officer2,272$31.16$2.0B-47.42%+36.80%$70.8K-100.00%Stalk
Sep 27, 2024BuyVRDNThomas W. BeethamChief Operating Officer5,000$23.41$2.0B-47.42%+36.80%$117.0K+500.00%Stalk
Sep 27, 2024BuyVRDNStephen F. MahoneyPresident and CEO21,400$23.33$2.0B-47.42%+36.80%$499.3KStalk